Streetbeat News

SCTL

Societal CDMO Inc

Employees

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

recro gainesville, llc, provides solid dosage form development, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market. specializing in extended release solid dose and dea controlled substances, recro has the experts to deliver clients’ most complex pharmaceutical development and manufacturing projects in its best-in-class, 97,000-square-foot manufacturing facility. for more information about recro’s flexible cdmo solutions, visit www.recrogainesville.com

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Societal CDMO has entered into a definitive agreement to be acquired by CoreRx. The acquisition price is set at $1.10 per share in cash. This strategic move is expected to enhance the combined entity's capabilities in the pharmaceutical manufacturing and development services sector.

Portfolio Pulse from Charles Gross

February 28, 2024 | 10:08 pm

Societal CDMO, Inc. (NASDAQ:SCTL) has announced a definitive agreement to be acquired by CoreRx, Inc. in a cash tender offer for all outstanding shares at $1.10 per share. The transaction, unanimously approved by Societal CDMO's board, is expected to close early in Q2 2024, subject to customary closing conditions. This merger aims to create an enhanced CDMO with broad capabilities in small molecule therapeutic development, from early-stage formulation to commercial manufacturing and packaging.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 10:08 pm

Trading for SCTL was halted but has now resumed as of 4:55:00 PM ET, following an update on quotation resumption times.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:55 pm

Trading for SCTL was halted at 4:21:18 p.m. ET due to pending news. The halt is a temporary measure until the news affecting the company is released.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:21 pm

In Wednesday's pre-market session, several healthcare stocks showed significant movement. Societal CDMO, Apollomics, Elicio Therapeutics, Scinai Immunotherapeutics, Renalytix, and PepGen were among the gainers, with increases ranging from 10.1% to 23.4%. Conversely, CytoMed Therapeutics, NanoString Technologies, Kazia Therapeutics, Exicure, GRI Bio, and Oragenics experienced declines between 7.76% and 16.9%. These movements reflect notable volatility in the healthcare sector, impacting the market value of these companies.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 1:06 pm

Societal CDMO and Benuvia have entered into a co-marketing agreement to jointly promote their complementary services in CDMO (Contract Development and Manufacturing Organization) and API (Active Pharmaceutical Ingredient) manufacturing to drug developers. This partnership aims to leverage the strengths of both companies to offer a more comprehensive service package to clients in the pharmaceutical industry.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:11 pm

In Tuesday's pre-market session, health care stocks saw significant movement. MorphoSys, Modular Medical, Akso Health Group, Assure Hldgs, Gain Therapeutics, and Societal CDMO were among the gainers, with increases ranging from 11.49% to 15.1%. Conversely, Allakos, Accelerate Diagnostics, Atreca, Evaxion Biotech, Inventiva, and Akanda were the losers, with declines between 10.64% and 56.5%.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 1:05 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Aura Biosciences (AURA) saw a 44.3% increase, while Galera Therapeutics (GRTX) rose 40.01%. Jin Medical International (ZJYL) and Seres Therapeutics (MCRB) also saw substantial gains. Conversely, Grifols (GRFS) and eFFECTOR Therapeutics (EFTR) faced sharp declines, along with Trevena (TRVN), Apollomics (APLM), Societal CDMO (SCTL), and Cyclacel Pharmaceuticals (CYCC).

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 1:06 pm

RBC Capital analyst Sean Dodge maintains an 'Outperform' rating on Societal CDMO (NASDAQ:SCTL) but lowers the price target from $2 to $1.25.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 7:04 pm

Societal CDMO (NASDAQ:SCTL) reported Q3 losses of $(0.05) per share, missing the analyst consensus estimate of $(0.02) by 150%. The company also reported quarterly sales of $23.59 million, missing the analyst consensus estimate of $24.25 million by 2.72%. However, both losses and sales show an increase compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 10:20 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.